Sukus, you still don't get it! Result is not bad
but result is not great neither, that is why NWBO needs support from journal.
If TLD meet primary endpoint and all other secondary endpoints, and if FDA agree OS as primary endpoint. NWBO doesn't need journal support and can just release TLD any time.
By the way, people here still hoping BUYOUT? Forget about it. Partnership? maybe...but it really depends on TLD. If TLD is not good enough, pretty much GAME OVER!
Market Data 
Markets 
AI
